Tidal Investments LLC Acquires Shares of 24,590 TG Therapeutics, Inc. $TGTX

Tidal Investments LLC bought a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 24,590 shares of the biopharmaceutical company’s stock, valued at approximately $1,351,000.

Other large investors have also modified their holdings of the company. Bank of America Corp DE grew its stake in TG Therapeutics by 71.7% during the 1st quarter. Bank of America Corp DE now owns 1,461,302 shares of the biopharmaceutical company’s stock valued at $48,544,000 after acquiring an additional 610,195 shares in the last quarter. Deutsche Bank AG purchased a new position in TG Therapeutics in the 2nd quarter worth approximately $12,937,000. Hsbc Holdings PLC lifted its stake in TG Therapeutics by 228.7% in the 4th quarter. Hsbc Holdings PLC now owns 146,087 shares of the biopharmaceutical company’s stock worth $4,374,000 after purchasing an additional 101,646 shares in the last quarter. PDT Partners LLC purchased a new position in TG Therapeutics in the 2nd quarter worth approximately $2,285,000. Finally, Gibbs Wealth Management boosted its holdings in shares of TG Therapeutics by 75.3% during the 1st quarter. Gibbs Wealth Management now owns 28,018 shares of the biopharmaceutical company’s stock worth $931,000 after purchasing an additional 12,032 shares during the last quarter. Hedge funds and other institutional investors own 58.58% of the company’s stock.

TG Therapeutics Stock Up 0.7%

Shares of NASDAQ TGTX opened at $56.87 on Friday. The company has a 50 day simple moving average of $53.43 and a 200-day simple moving average of $44.55. The company has a market capitalization of $8.71 billion, a P/E ratio of 20.76, a P/E/G ratio of 2.42 and a beta of 1.67. The company has a debt-to-equity ratio of 1.23, a current ratio of 4.27 and a quick ratio of 3.72. TG Therapeutics, Inc. has a 1 year low of $26.76 and a 1 year high of $59.30.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.26). TG Therapeutics had a net margin of 55.22% and a return on equity of 73.49%. The business had revenue of $240.34 million during the quarter, compared to analyst estimates of $229.77 million. During the same quarter in the prior year, the company posted $0.17 earnings per share. The company’s revenue was up 70.2% on a year-over-year basis. On average, equities research analysts predict that TG Therapeutics, Inc. will post 0.92 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on TGTX shares. Zacks Research lowered TG Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, September 7th. B. Riley Financial boosted their price objective on TG Therapeutics from $55.00 to $86.00 and gave the stock a “buy” rating in a research note on Monday, July 27th. HC Wainwright restated a “buy” rating and issued a $78.00 target price on shares of TG Therapeutics in a report on Tuesday, September 1st. Bank of America raised their target price on TG Therapeutics from $17.00 to $20.00 and gave the stock an “underperform” rating in a research note on Tuesday, July 7th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $83.00 price target on shares of TG Therapeutics in a report on Monday, June 22nd. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $63.00.

Insider Transactions at TG Therapeutics

In other TG Therapeutics news, Director Laurence Charney sold 5,000 shares of TG Therapeutics stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $54.96, for a total value of $274,800.00. Following the sale, the director owned 168,640 shares in the company, valued at $9,268,454.40. The trade was a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 8.87% of the stock is currently owned by company insiders.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for B-cell diseases and autoimmune disorders. The company’s research and development programs are centered on therapies that target B cells, which play an important role in several immune-mediated conditions.

TG Therapeutics’ principal product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved by the U.S. Food and Drug Administration for the treatment of adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis.